# US 2026/0242365 A1 · Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242365 A1
- Document ID: US20260242365A1
- Status: Published application
- Kind: A1
- Application number: 19/156,134
- Filed: 2024-02-14
- Published: 2026-08-20
- Earliest claimed: 2023-02-15
- Assignees: Insmed Incorporated
- Applicants: Insmed Incorporated
- Inventors: Adam J. PLAUNT
- Web page: https://patentgrep.com/patent/US20260242365A1

## CPC

- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 11/00: Drugs for disorders of the respiratory system
- C07D 267/10: not condensed with other rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compositions comprising an effective amount of a DPP1 inhibitor of Formula (I), or a pharmaceutically acceptable salt thereof, and their use in treating disorders mediated by dipeptidyl peptidase 1 (DPP1). In embodiments of the methods provided herein, the composition is administered orally, once-a-day.

## Claims

### Claim 1

A method of treating a disorder mediated by dipeptidyl peptidase 1 (DPP1) in a subject in need of treatment, comprising administering a composition comprising an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, to the subject for an administration period:
wherein,
G is a 5-12 membered carbon ring, a 5-12 membered monocyclic heterocycle containing 1-3 heteroatoms selected from N, S or O or the fused ring of formula
L1 bonds G by replacing any hydrogen atom on ring G, and is a bond, C1-3 alkylene, —NH—, —N(C1-4alkyl)-, —O—, —S—, C2-6ortho-alkenyl, C2-6ortho-alkynyl, —CO— or —CONH—, wherein the alkylene, ortho-alkenyl or ortho-alkynyl is optionally substituted with 1-3 halogen, C1-4 alkyl, cyano, hydroxyl, NH2 and —COOH groups;
R1, R2 and R3 are independently selected from H, deuterium, halogen, C1-4alkyl, C1-4alkoxy, C2-6 alkenyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl and a 4-7 membered heterocycle containing 1-3 heteroatoms selected from N, S or O, the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl and heterocycle having arbitrarily undergone substitution with 1-3 groups selected from halogen, C1-4alkyl, cyano, hydroxyl, NH2 and COOH; alternatively, R1 and R2 form a C3-6cycloalkyl or a 4-7 membered heterocycle containing 1-3 heteroatoms selected from N, S or O, wherein the cycloalkyl or heterocycle is optionally substituted with 1-3 groups selected from ═O, halogen, cyano, hydroxyl, NH2, COOH, C1-4 alkyl, C2-6 alkenyl, C2-6alkynyl and C3-6cycloalkyl;
Y1 and Y2 are both independently selected from CR4 or N;
each R4 is independently selected from H, deuterium, halogen, C1-4 alkyl, C1-4 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6cycloalkyl, cyano, hydroxyl, NH2, NHC1-4 alkyl, N(C1-4 alkyl) 2, COOH, COC1-4 alkyl, COOC1-4 alkyl, CONHC1-4 alkyl, CON(C1-4 alkyl) 2, NHCOC1-4 alkyl, and a 4-7 membered heterocycle containing 1-3 heteroatoms selected from N, S or O; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and heterocycle groups within R4 are optionally substituted with 1-3 groups selected from deuterium, halogen, cyano, hydroxyl, NH2 and COOH;
X1, X2, X3 and X4 are each independently selected from a bond, NR5, O, CR6R7, S, S(O) and S(O) 2, and wherein at most one of X1, X2, X3 and X4 is a bond;
Rc is H, —O, halogen, cyano, hydroxyl, NH2, —COOH, C1-4 alkyl, halogenated C1-4 alkyl, hydroxyl C1-4 alkyl, C1-4 alkoxy, C1-6 alkoxyalkyl or halogenated C1-4 alkoxy;
each R5 is independently selected from H, C1-4 alkyl, —COC1-4 alkyl, C2-6 alkenyl, C2-6alkynyl and C3-6cycloalkyl; wherein the alkyl, alkenyl, alkynyl and cycloalkyl is optionally substituted with 1-3 groups selected from deuterium, halogen, cyano, hydroxyl, NH2 and COOH;
R6 and R7 are each independently selected from H, deuterium, halogen, C1-4 alkyl, C1-4alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-6cycloalkyl, cyano, hydroxyl, NH2, COOH, and a 4-7 membered heterocycle containing 1-3 heteroatoms selected from N, S or O, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl and heterocycle is optionally substituted with 1-3 groups arbitrarily selected from deuterium, halogen, cyano, hydroxyl, NH2 and —COOH;
alternatively, R6 and R7 form ═O;
alternatively, two R5 on the atoms in adjacent rings or two R6 on the atoms in adjacent rings within X1, X2, X3 and X4, or the R5 and R6 of atoms on adjacent rings and the atoms binding to them form double-bonds;
alternatively, the R6 and R7 on the same carbon atom form a C3-12 carbon ring with the carbon atoms linked to them or a 4-7 membered heterocycle containing 1-3 heteroatoms selected from N, S or O, said carbon ring or heterocycle having arbitrarily undergone substitution with 1-3 groups selected from ═O, halogen, cyano, hydroxyl, NH2, —COOH, C1-4 alkyl, C2-6 alkenyl, C2-6 alkynyl and C3-6 cycloalkyl;
Z is CH or N;
A is
a hexatomic heteroaryl or 5-7 membered non-aromatic monocyclic heterocycle, wherein the heteroaryl and non-aromatic monocyclic heterocycle contains 1-3 heteroatoms selected from N, S or O;
B is a C4-6 carbon ring or a 5-6 membered heterocycle containing 1-3 heteroatoms selected from N, S or O; and
each R8 is independently selected from H, ═O, deuterium, halogen, C1-4 alkyl, C1-4 alkoxy, SC1-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, cyano, hydroxyl, —COOH, NH2 and C3-6 cycloalkyl; said alkyl, alkoxy, alkenyl, alkynyl or cycloalkyl having arbitrarily undergone substitution with 1-3 groups selected from deuterium, halogen, cyano, hydroxyl, NH2 and COOH.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is a compound of Formula (1a), or a pharmaceutically acceptable salt thereof:
wherein
Rc is ═O, halogen, cyano, hydroxyl, NH2, —COOH, C1-4 alkyl, halogenated C1-4 alkyl, hydroxyl C1-4 alkyl, C1-4 alkoxy, C1-6 alkoxyalkyl or halogenated C1-4 alkoxy.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is a compound of Formula (1b), or a pharmaceutically acceptable salt thereof:
wherein
Rc is ═O, halogen, cyano, hydroxyl, NH2, —COOH, C1-4 alkyl, halogenated C1-4 alkyl, hydroxyl C1-4 alkyl, C1-4 alkoxy, C1-6 alkoxyalkyl or halogenated C1-4 alkoxy.

### Claim 4 (depends on 1)

The method of claim 1, wherein G is

### Claim 5 (depends on 1)

The method of claim 1, wherein G is

### Claim 6 (depends on 1)

The method of claim 1, wherein G is

### Claim 7 (depends on 1)

The method of claim 1, wherein G is

### Claim 8 (depends on 1)

The method of claim 1, wherein G is a substituted cyclopentane, cyclohexane, cycloheptane or benzene,

### Claim 9 (depends on 1)

The method of claim 1, wherein G is:

### Claim 10 (depends on 1)

The method of claim 1, wherein G is

### Claim 11 (depends on 1)

The method of claim 1, wherein G is

### Claim 12 (depends on 1)

The method of claim 1, wherein G is

### Claim 13 (depends on 1)

The method of claim 1, wherein R1 is H.

### Claim 14 (depends on 1)

The method of claim 1, wherein R2 is H.

### Claim 15 (depends on 1)

The method of claim 1, wherein R3 is H.

### Claim 16 (depends on 1)

The method of claim 1, wherein Rc is hydroxyl, C1-4 alkyl, or C1-4 alkoxy.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein Rc is methoxy.

### Claim at position 19

-36. (canceled)

### Claim 37 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is one of the following compounds:
or
a pharmaceutically acceptable salt thereof.

### Claim 38 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim at position 22

-48. (canceled)

### Claim 49 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim at position 24

-149. (canceled)
